Voyager Therapeutics, a gene therapy biotech targeting Parkinson's disease and other CNS disorders, raised $70 million by offering 5.0 million shares at $14, below the range of $15 to $17. It had originally planned to offer 4.69 million shares. Voyager Therapeutics plans to list on the Nasdaq under the symbol VYGR. Cowen & Company and Piper Jaffray acted as lead managers on the deal.
